|
|
Volumn 5, Issue 4, 2003, Pages 270-277
|
|
Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTIRHEUMATIC AGENT;
IMMUNOGLOBULIN G;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR RECEPTOR;
CHEMICALLY INDUCED DISORDER;
CONGESTIVE HEART FAILURE;
DEMYELINATING DISEASE;
DRUG ANTAGONISM;
HUMAN;
INCIDENCE;
LYMPHOMA;
REVIEW;
RHEUMATOID ARTHRITIS;
RISK;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
DEMYELINATING DISEASES;
HEART FAILURE, CONGESTIVE;
HUMANS;
IMMUNOGLOBULIN G;
INCIDENCE;
LYMPHOMA;
ODDS RATIO;
RECEPTORS, TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0642366755
PISSN: 15233774
EISSN: None
Source Type: Journal
DOI: 10.1007/s11926-003-0005-9 Document Type: Review |
|
Times cited : (31)
|
|
References (37)
|
